Solving the Puzzle of What Makes Immunotherapies Work

Overview

Journal Trends Cancer

Publisher Cell Press

Specialty Oncology

Date 2022 Aug 6

PMID 35933298

Authors

Xiaoxiao Ma

Timothy A Chan

Affiliations

Soon will be listed here.

Abstract

The rapid adoption of immune checkpoint blockade (ICB) therapies has led to a need to understand the mechanistic drivers of efficacy and the identification of novel biomarkers that enrich for patients who benefit from ICB therapy. Here, we provide a perspective on emerging biomarker candidates, their underlying biological mechanisms, and how they may fit into the current landscape of ICB biomarkers. We discuss new frameworks to identify and evaluate biomarker candidates and review the opportunities and challenges of utilizing biomarker-derived models to facilitate the development of new immunotherapies.

Citing Articles

CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer.

He X, Liu J, Zhou Y, Zhao S, Chen Z, Xu Z Cell Death Differ. 2025; .

PMID: 39972059 DOI: 10.1038/s41418-025-01464-0.

Establishing a model composed of immune-related gene-modules to predict tumor immunotherapy response.

Fu D, Weng X, Su Y, Hong B, Zhao A, Lin J Sci Rep. 2024; 14(1):16630.

PMID: 39025898 PMC: 11258235. DOI: 10.1038/s41598-024-67742-y.

Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer.

Wang S, Wu C, He M, Yong J, Chen Y, Qian L Nat Commun. 2024; 15(1):1515.

PMID: 38373991 PMC: 10876971. DOI: 10.1038/s41467-024-45479-6.

Sequential Chromogenic IHC: Spatial Analysis of Lymph Nodes Identifies Contact Interactions between Plasmacytoid Dendritic Cells and Plasmablasts.

Claudio N, Nguyen M, Wanner A, Pucci F Cancer Res Commun. 2023; 3(7):1237-1247.

PMID: 37484199 PMC: 10361537. DOI: 10.1158/2767-9764.CRC-23-0102.

New frontiers in immune checkpoint B7-H3 (CD276) research and drug development.

Getu A, Tigabu A, Zhou M, Lu J, Fodstad O, Tan M Mol Cancer. 2023; 22(1):43.

PMID: 36859240 PMC: 9979440. DOI: 10.1186/s12943-023-01751-9.

References

Haslam A, Prasad V . Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019; 2(5):e192535. PMC: 6503493. DOI: 10.1001/jamanetworkopen.2019.2535. View

Jones P, Ohtani H, Chakravarthy A, De Carvalho D . Epigenetic therapy in immune-oncology. Nat Rev Cancer. 2019; 19(3):151-161. DOI: 10.1038/s41568-019-0109-9. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Gandhi L, Garassino M . Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med. 2018; 379(11):e18. DOI: 10.1056/NEJMc1808567. View

Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

Naranbhai V, Viard M, Dean M, Groha S, Braun D, Labaki C . HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021; 23(1):172-184. PMC: 8742225. DOI: 10.1016/S1470-2045(21)00582-9. View

Yoo S, Chowell D, Valero C, Morris L, Chan T . Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. JAMA Netw Open. 2022; 5(2):e220448. PMC: 8886536. DOI: 10.1001/jamanetworkopen.2022.0448. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

Chowell D, Yoo S, Valero C, Pastore A, Krishna C, Lee M . Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol. 2021; 40(4):499-506. PMC: 9363980. DOI: 10.1038/s41587-021-01070-8. View

10.

Colen R, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N . Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021; 9(4). PMC: 8051405. DOI: 10.1136/jitc-2020-001752. View

11.

Boesch M, Baty F, Rothschild S, Tamm M, Joerger M, Fruh M . Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer. 2021; 125(3):313-323. PMC: 8329167. DOI: 10.1038/s41416-021-01365-2. View

12.

Wang M, Zhai X, Li J, Guan J, Xu S, Li Y . The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Front Immunol. 2021; 12:670391. PMC: 8339552. DOI: 10.3389/fimmu.2021.670391. View

13.

Sayaman R, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J . Germline genetic contribution to the immune landscape of cancer. Immunity. 2021; 54(2):367-386.e8. PMC: 8414660. DOI: 10.1016/j.immuni.2021.01.011. View

14.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

15.

Bessell C, Isser A, Havel J, Lee S, Bell D, Hickey J . Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight. 2020; 5(8). PMC: 7205429. DOI: 10.1172/jci.insight.135597. View

16.

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

17.

Rock K, Reits E, Neefjes J . Present Yourself! By MHC Class I and MHC Class II Molecules. Trends Immunol. 2016; 37(11):724-737. PMC: 5159193. DOI: 10.1016/j.it.2016.08.010. View

18.

Marty R, Kaabinejadian S, Rossell D, Slifker M, van de Haar J, Engin H . MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell. 2017; 171(6):1272-1283.e15. PMC: 5711564. DOI: 10.1016/j.cell.2017.09.050. View

19.

Blass E, Ott P . Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021; 18(4):215-229. PMC: 7816749. DOI: 10.1038/s41571-020-00460-2. View

20.

Kather J, Pearson A, Halama N, Jager D, Krause J, Loosen S . Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nat Med. 2019; 25(7):1054-1056. PMC: 7423299. DOI: 10.1038/s41591-019-0462-y. View